From the Guidelines
Some people with rheumatoid arthritis (RA) may experience a temporary worsening of symptoms when starting methotrexate, but this is not the typical response for most patients. These initial side effects can include fatigue, nausea, mouth sores, headaches, and occasionally a brief flare of joint pain that typically resolves within the first few weeks of treatment 1. Methotrexate usually takes 4-8 weeks to demonstrate its full therapeutic benefit, so patience during this initial period is important. The standard starting dose is typically 7.5-15 mg once weekly, often with folic acid supplementation (1 mg daily or 5-10 mg weekly, taken 24 hours after methotrexate) to reduce side effects 2. If initial side effects are troublesome, splitting the dose over 24 hours or switching to subcutaneous injection can improve tolerability. It's essential to continue the medication as prescribed unless severe side effects occur, as premature discontinuation may prevent achieving the drug's beneficial effects. The delayed onset of action occurs because methotrexate works by gradually modulating the immune system and reducing inflammation, rather than providing immediate symptomatic relief like pain medications. Key points to consider when initiating methotrexate therapy include:
- Starting with a dose of 10-15 mg/week and escalating as needed and tolerated 1
- Using folic acid supplementation to reduce side effects 2
- Monitoring for side effects and adjusting the dose or route of administration as needed 3
- Considering the use of methotrexate in combination with other disease-modifying antirheumatic drugs (DMARDs) or biologic agents if necessary 4
From the Research
Initial Response to Methotrexate in RA Patients
- The provided studies do not directly address whether people with RA get worse on methotrexate initially 5, 6, 7, 8, 9.
- However, it is known that methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA) and is often used as the initial treatment 5, 7.
- The efficacy and safety of methotrexate have been well established, with studies showing that it has one of the best efficacy/toxicity ratios among DMARDs 7.
- Some patients may experience side effects such as cytopenias, gastrointestinal adverse events, or abnormal liver function tests, which may limit its use 8.
- The treatment of RA is a dynamic process, and maintaining a delicate balance between benefits and risks is crucial 7.
Biomarkers and Treatment Response
- Various studies have evaluated the role of potential biomarkers in predicting treatment effectiveness of methotrexate, including RBC MTX polyglutamate (PG) levels, genetic variation, gene expression profiles, and serum proteins 8.
- These biomarkers may help identify patients who are more likely to respond to methotrexate treatment, but more research is needed to fully understand their role 8.
Combination Therapy
- Methotrexate can be used in combination with other conventional synthetic DMARDs, biologic drugs, or tofacitinib to achieve better disease control 9.
- Studies have shown that combination therapy with methotrexate and other DMARDs can be effective in controlling disease activity and is generally well tolerated 9.